Risk factors for post-transplant diabetes mellitus in renal transplant: Role of genetic variability in the CYP450-mediated arachidonic acid metabolism

Molecular and Cellular Endocrinology

Volumn 419, Issue , 2016, Pages 158-164

  Gervasini, Guillermo ^a   Luna, Enrique ^b   García Cerrada, Montserrat ^a   García Pino, Guadalupe ^b   Cubero, Juan José ^b  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

Cyclosporine; Post transplant diabetes mellitus; Renal transplant; Risk factors; Tacrolimus

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2J2; CYTOCHROME P450 4A11; CYTOCHROME P450 4F2; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; TACROLIMUS; UNCLASSIFIED DRUG; CYP4F2 PROTEIN, HUMAN; CYTOCHROME P450 FAMILY 4; HYDROXYICOSATETRAENOIC ACID;

ADULT; AGE; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; CREATININE CLEARANCE; CYP4F2 GENE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EXPOSURE; FATTY ACID METABOLISM; FATTY ACID SYNTHESIS; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLOMERULONEPHRITIS; GRAFT RECIPIENT; HETEROZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT INDICATION; ADVERSE EFFECTS; GENETICS; KIDNEY TRANSPLANTATION; METABOLISM; MIDDLE AGED;

ADULT; AGE FACTORS; ARACHIDONIC ACID; BODY MASS INDEX; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROME P450 FAMILY 4; DIABETES MELLITUS; FEMALE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84949595386     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.10.009     Document Type: Article

References (61)

1. Alkayed N.J., Goyagi T., Joh H.D., Klaus J., Harder D.R., Traystman R.J., Hurn P.D. Neuroprotection and P450 2C11 upregulation after experimental transient ischemic attack. Stroke 2002, 33:1677-1684.
2. Bahadur N., Leathart J.B., Mutch E., Steimel-Crespi D., Dunn S.A., Gilissen R., Houdt J.V., Hendrickx J., Mannens G., Bohets H., Williams F.M., Armstrong M., Crespi C.L., Daly A.K. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem. Pharmacol. 2002, 64:1579-1589.
3. Burgess A.P., Vanella L., Bellner L., Gotlinger K., Falck J.R., Abraham N.G., Schwartzman M.L., Kappas A. Heme oxygenase (HO-1) rescue of adipocyte dysfunction in HO-2 deficient mice via recruitment of epoxyeicosatrienoic acids (EETs) and adiponectin. Cell. Physiol. Biochem. 2012, 29:99-110.
4. Burgess A., Vanella L., Bellner L., Schwartzman M.L., Abraham N.G. Epoxyeicosatrienoic acids and heme oxygenase-1 interaction attenuates diabetes and metabolic syndrome complications. Prostagl. Other Lipid Mediat. 2012, 97:1-16.
5. Cole E.H., Prasad G.V., Cardella C.J., Kim J.S., Tinckam K.J., Cattran D.C., Schiff J.R., Landsberg D.N., Zaltzman J.S., Gill J.S. A pilot study of reduced dose cyclosporine and corticosteroids to reduce new onset diabetes mellitus and acute rejection in kidney transplant recipients. Transpl. Res. 2013, 2:1.
6. Cosio F.G., Pesavento T.E., Kim S., Osei K., Henry M., Ferguson R.M. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int. 2002, 62:1440-1446.
7. Cosio F.G., Kudva Y., van der Velde M., Larson T.S., Textor S.C., Griffin M.D., Stegall M.D. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005, 67:2415-2421.
8. Courivaud C., Ladriere M., Toupance O., Caillard S., Hurault de Ligny B., Ryckelynck J.P., Moulin B., Rieu P., Frimat L., Chalopin J.M., Chauve S., Kazory A., Ducloux D. Impact of pre-transplant dialysis modality on post-transplant diabetes mellitus after kidney transplantation. Clin. Transplant. 2011, 25:794-799.
9. Dai D., Zeldin D.C., Blaisdell J.A., Chanas B., Coulter S.J., Ghanayem B.I., Goldstein J.A. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001, 11:597-607.
10. Davidson J.A., Wilkinson A. New-onset diabetes after transplantation 2003 International consensus guidelines: an endocrinologist's view. Diabetes Care 2004, 27:805-812.
11. Dolegowska B., Blogowski W., Domanski L. Is it possible to predict the early post-transplant allograft function using 20-HETE measurements? A preliminary report. Transpl. Int. 2009, 22:546-553.
12. Ducloux D., Motte G., Vautrin P., Bresson-Vautrin C., Rebibou J.M., Chalopin J.M. Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus. Nephrol. Dial. Transplant. 1999, 14:1244-1246.
13. Eid S., Maalouf R., Jaffa A.A., Nassif J., Hamdy A., Rashid A., Ziyadeh F.N., Eid A.A. 20-HETE and EETs in diabetic nephropathy: a novel mechanistic pathway. PLoS One 2013, 8:e70029.
14. Eid S., Abou-Kheir W., Sabra R., Daoud G., Jaffa A., Ziyadeh F.N., Roman L., Eid A.A. Involvement of renal cytochromes P450 and arachidonic acid metabolites in diabetic nephropathy. J. Biol. Regul. Homeost. Agents 2013, 27:693-703.
15. Fan F., Muroya Y., Roman R.J. Cytochrome P450 eicosanoids in hypertension and renal disease. Curr. Opin. Nephrol. Hypertens. 2015, 24:37-46.
16. Fava C., Montagnana M., Danese E., Sjogren M., Almgren P., Guidi G.C., Hedblad B., Engstrom G., Minuz P., Melander O. The functional variant V433M of the CYP4F2 and the metabolic syndrome in Swedes. Prostagl. Other Lipid Mediat. 2012, 98:31-36.
17. Gainer J.V., Bellamine A., Dawson E.P., Womble K.E., Grant S.W., Wang Y., Cupples L.A., Guo C.Y., Demissie S., O'Donnell C.J., Brown N.J., Waterman M.R., Capdevila J.H. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005, 111:63-69.
18. Gangadhariah M.H., Luther J.M., Garcia V., Paueksakon P., Zhang M.Z., Hayward S.W., Love H.D., Falck J.R., Manthati V.L., Imig J.D., Schwartzman M.L., Zent R., Capdevila J.H., Pozzi A. Hypertension is a major contributor to 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic nephropathy. J. Am. Soc. Nephrol. 2015, 26:597-610.
19. Gaynor J.J., Ciancio G., Guerra G., Sageshima J., Hanson L., Roth D., Goldstein M.J., Chen L., Kupin W., Mattiazzi A., Tueros L., Flores S., Barba L.J., Lopez A., Rivas J., Ruiz P., Vianna R., Burke G.W. Multivariable risk of developing new onset diabetes after transplant-results from a single-center study of 481 adult, primary kidney transplant recipients. Clin. Transplant. 2015, 29:301-310.
20. Gervasini G., Garcia M., Macias R.M., Benitez J., Caravaca F., Cubero J.J. CYP2C8*3 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors. J. Clin. Pharmacol. 2013, 53:427-434.
21. Gervasini G., García-Cerrada M., Coto E., Vergara E., García-Pino G., Alvarado R., Fernández-Cavada M.J., Suárez-Álvarez B., Barroso S., Doblaré E., Díaz-Corte C., López-Larrea C., Cubero J.J. A 3'-UTR polymorphism in soluble epoxide hydrolase gene is associated with acute rejection in renal transplant recipients. PLoS One 2015, 10:e0133563.
22. Gervasini G., García-Cerrada M., Vergara E., García-Pino G., Alvarado R., Fernández-Cavada M.J., Barroso S., Doblaré E., Cubero J.J. Polymorphisms in CYP-mediated arachidonic acid routes affect the outcome of renal transplantation. Eur. J. Clin. Investig. 2015, 45:1060-1068.
23. Hjelmesaeth J., Hartmann A., Leivestad T., Holdaas H., Sagedal S., Olstad M., Jenssen T. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int. 2006, 69:588-595.
24. Hoff U., Lukitsch I., Chaykovska L., Ladwig M., Arnold C., Manthati V.L., Fuller T.F., Schneider W., Gollasch M., Muller D.N., Flemming B., Seeliger E., Luft F.C., Falck J.R., Dragun D., Schunck W.H. Inhibition of 20-HETE synthesis and action protects the kidney from ischemia/reperfusion injury. Kidney Int. 2011, 79:57-65.
25. Hoopes S.L., Garcia V., Edin M.L., Schwartzman M.L., Zeldin D.C. Vascular actions of 20-HETE. Prostagl. Other Lipid Mediat. 2015, 120:9-16.
26. Hu B.C., Li Y., Li F.H., Zhang Y., Sheng C.S., Fan H.Q., Wang J.G. Peripheral and central augmentation indexes in relation to the CYP4F2 polymorphisms in Chinese. J. Hypertens. 2011, 29:501-508.
27. Imig J.D. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. Ren. Physiol. 2005, 289:F496-F503.
28. Issan Y., Hochhauser E., Guo A., Gotlinger K.H., Kornowski R., Leshem-Lev D., Lev E., Porat E., Snir E., Thompson C.I., Abraham N.G., Laniado-Schwartzman M. Elevated level of pro-inflammatory eicosanoids and EPC dysfunction in diabetic patients with cardiac ischemia. Prostagl. Other Lipid Mediat. 2013, 100-101:15-21.
29. Johnston O., Rose C.L., Webster A.C., Gill J.S. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J. Am. Soc. Nephrol. 2008, 19:1411-1418.
30. Kasiske B.L., Snyder J.J., Gilbertson D., Matas A.J. Diabetes mellitus after kidney transplantation in the United States. Am. J. Transpl. 2003, 3:178-185.
31. Kaysen G.A. Biochemistry and biomarkers of inflamed patients: why look, what to assess. Clin. J. Am. Soc. Nephrol. 2009, 4(Suppl. 1):S56-S63.
32. King L.M., Ma J., Srettabunjong S., Graves J., Bradbury J.A., Li L., Spiecker M., Liao J.K., Mohrenweiser H., Zeldin D.C. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol. Pharmacol. 2002, 61:840-852.
33. Lasker J.M., Chen W.B., Wolf I., Bloswick B.P., Wilson P.D., Powell P.K. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J. Biol. Chem. 2000, 275:4118-4126.
34. Lee S.H., Lee J., Cha R., Park M.H., Ha J.W., Kim S., Kim Y.S. Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation. Transpl. Proc. 2008, 40:1353-1356.
35. Lee C.R., Imig J.D., Edin M.L., Foley J., DeGraff L.M., Bradbury J.A., Graves J.P., Lih F.B., Clark J., Myers P., Perrow A.L., Lepp A.N., Kannon M.A., Ronnekleiv O.K., Alkayed N.J., Falck J.R., Tomer K.B., Zeldin D.C. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. Faseb J. 2010, 24:3770-3781.
36. Li X., Zhao G., Ma B., Li R., Hong J., Liu S., Wang D.W. 20-Hydroxyeicosatetraenoic acid impairs endothelial insulin signaling by inducing phosphorylation of the insulin receptor substrate-1 at Ser616. PLoS One 2014, 9:e95841.
37. Marrero D., Hernandez D., Tamajon L.P., Rivero M., Lampreabe I., Checa M.D., Gonzalez-Posada J.M. Pre-transplant weight but not weight gain is associated with new-onset diabetes after transplantation: a multi-centre cohort Spanish study. NDT Plus 2010, 3:ii15-ii20.
38. Miyata N., Roman R.J. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J. Smooth Muscle Res. 2005, 41:175-193.
39. Murakami N., Riella L.V., Funakoshi T. Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. Am. J. Transpl. 2014, 14:2317-2327.
40. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., Zeldin D.C., Liao J.K. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285:1276-1279.
41. Numakura K., Satoh S., Tsuchiya N., Horikawa Y., Inoue T., Kakinuma H., Matsuura S., Saito M., Tada H., Suzuki T., Habuchi T. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantation 2005, 80:1419-1424.
42. Paller M.S., Jacob H.S. Cytochrome P-450 mediates tissue-damaging hydroxyl radical formation during reoxygenation of the kidney. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:7002-7006.
43. Rakel A., Karelis A.D. New-onset diabetes after transplantation: risk factors and clinical impact. Diabetes Metabol. 2011, 37:1-14.
44. Regner K.R., Zuk A., Van Why S.K., Shames B.D., Ryan R.P., Falck J.R., Manthati V.L., McMullen M.E., Ledbetter S.R., Roman R.J. Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injury. Kidney Int. 2009, 75:511-517.
45. Rettie A.E., Wienkers L.C., Gonzalez F.J., Trager W.F., Korzekwa K.R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994, 4:39-42.
46. Rodrigo E., Pinera C., de Cos M.A., Sanchez B., Ruiz J.C., Fernandez-Fresnedo G., Palomar R., Gonzalez-Cotorruelo J., Gomez-Alamillo C., de Castro S.S., de Francisco A.L., Arias M. Evolution of tacrolimus blood levels and concentration-dose ratios in patients who develop new onset diabetes mellitus after kidney transplantation. Transpl. Int. 2005, 18:1152-1157.
47. Sharma M., McCarthy E.T., Reddy D.S., Patel P.K., Savin V.J., Medhora M., Falck J.R. 8,9-Epoxyeicosatrienoic acid protects the glomerular filtration barrier. Prostagl. Other Lipid Mediat 2009, 89:43-51.
48. Stec D.E., Roman R.J., Flasch A., Rieder M.J. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol. Genomics 2007, 30:74-81.
49. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., Zhang Z.Y., Kaminsky L.S., Shenfield G.M., Miners J.O., Birkett D.J., Goldstein J.A. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996, 6:341-349.
50. Sumrani N.B., Delaney V., Ding Z.K., Davis R., Daskalakis P., Friedman E.A., Butt K.M., Hong J.H. Diabetes mellitus after renal transplantation in the cyclosporine era-an analysis of risk factors. Transplantation 1991, 51:343-347.
51. Tessaro F.H., Ayala T.S., Martins J.O. Lipid mediators are critical in resolving inflammation: a review of the emerging roles of eicosanoids in diabetes mellitus. Biomed. Res. Int. 2015, 2015:568408.
52. Tufton N., Ahmad S., Rolfe C., Rajkariar R., Byrne C., Chowdhury T.A. New-onset diabetes after renal transplantation. Diabet. Med. 2014, 31:1284-1292.
53. Vincenti F., Schena F.P., Paraskevas S., Hauser I.A., Walker R.G., Grinyo J. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am. J. Transpl. 2008, 8:307-316.
54. Ward N.C., Tsai I.J., Barden A., van Bockxmeer F.M., Puddey I.B., Hodgson J.M., Croft K.D. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. Hypertension 2008, 51:1393-1398.
55. Ward N.C., Croft K.D., Puddey I.B., Phillips M., van Bockxmeer F., Beilin L.J., Barden A.E. The effect of a single nucleotide polymorphism of the CYP4F2 gene on blood pressure and 20-hydroxyeicosatetraenoic acid excretion after weight loss. J. Hypertens. 2014, 32:1495-1502. discussion 1502.
56. Webster A.C., Woodroffe R.C., Taylor R.S., Chapman J.R., Craig J.C. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005, 331:810.
57. Woodward R.S., Schnitzler M.A., Baty J., Lowell J.A., Lopez-Rocafort L., Haider S., Woodworth T.G., Brennan D.C. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am. J. Transpl. 2003, 3:590-598.
58. Wu S., Chen W., Murphy E., Gabel S., Tomer K.B., Foley J., Steenbergen C., Falck J.R., Moomaw C.R., Zeldin D.C. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J. Biol. Chem. 1997, 272:12551-12559.
59. Yang L., Maki-Petaja K., Cheriyan J., McEniery C., Wilkinson I.B. The role of epoxyeicosatrienoic acids in the cardiovascular system. Br. J. Clin. Pharmacol. 2015, 80:28-44.
60. Zeldin D.C. Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem. 2001, 276:36059-36062.
61. Zeldin D.C., Moomaw C.R., Jesse N., Tomer K.B., Beetham J., Hammock B.D., Wu S. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch. Biochem. Biophys. 1996, 330:87-96.